QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Fully human anti-PD-L1 IgG1 lambda monoclonal antibody

Recombinant human anti-VEGF IgG1 monoclonal antibody

5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine

(SP-4-2)-diamminedichloroplatinum(II)

2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

5-fluoro-2,4 (1H,3H)-pyrimidinedione

Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)

5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

omega-3-acid ethyl esters)

(SBRT)

recombinant human super agonist interleukin-15 (IL-15) complex

adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-CEA (carcinoembryonic antigen)

Ad5 \[E1-, E2b-\]-Brachyury

Ad5 \[E1-, E2b-\]-mucin 1 (MUC1)

RAS yeast vaccine

CEA yeast vaccine

Brachyury yeast vaccine

NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)